This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
by Zacks Equity Research
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
BSXNegative Net Change HQYNegative Net Change GKOSNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
BAX Stock Falls Following Q3 Earnings Beat & Sales Miss, '25 EPS View Down
by Zacks Equity Research
Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.
BSXNegative Net Change BAXPositive Net Change HQYNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
CAH Q1 Earnings Beat Estimates, '26 EPS View Up, Stock Gains
by Zacks Equity Research
Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.
BSXNegative Net Change CAHNegative Net Change HQYNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?
by Moumi Mondal
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
ABTNegative Net Change HOLXPositive Net Change
medical medical-devices
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
by Zacks Equity Research
BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.
BSXNegative Net Change ISRGPositive Net Change BIONegative Net Change MEDPPositive Net Change
earnings medical medical-devices
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
by Debanjana Dey
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
VEEVNegative Net Change INSPNegative Net Change TXGNegative Net Change HIMSNegative Net Change
earnings medical medical-devices
CVS Stock Falls Despite Q3 Earnings & Revenue Beat, '25 EPS View Up
by Zacks Equity Research
CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.
BSXNegative Net Change ISRGPositive Net Change CVSNegative Net Change MEDPPositive Net Change
earnings medical medical-devices
GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls
by Zacks Equity Research
GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.
BSXNegative Net Change HQYNegative Net Change GEHCPositive Net Change SOLVPositive Net Change
earnings medical medical-devices
ISRG vs BSX: Comparing Q3 Earnings, Growth Strategies and Prospects
by Indrajit Bandyopadhyay
Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.
BSXNegative Net Change ISRGPositive Net Change
medical medical-devices
Bull of the Day: Intuitive Surgical (ISRG)
by Jeremy Mullin
This leading surgical robotic stock surges on strong earnings and growing global adoption.
ISRGPositive Net Change
medical medical-devices
Intuitive Surgical and Oklo have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuitive Surgical surges after a strong earnings beat and upbeat outlook, while Oklo faces falling estimates and valuation pressure ahead of results.
ISRGPositive Net Change AMPPositive Net Change RKTNegative Net Change SANNegative Net Change OKLONegative Net Change
medical-devices
ECL Stock Falls in Pre-Market Despite Q3 Earnings Beat, Margins Expand
by Zacks Equity Research
Ecolab tops third-quarter 2025 estimates with strong margin gains and lifts full-year EPS outlook amid steady segment growth.
ECLNegative Net Change IDXXNegative Net Change HQYNegative Net Change DOCSNegative Net Change
earnings medical medical-devices
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
by Zacks Equity Research
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
DVAPositive Net Change EHCNegative Net Change ELANNegative Net Change AVAHPositive Net Change
earnings medical medical-devices
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
by Zacks Equity Research
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
ABTNegative Net Change DXCMPositive Net Change PODDNegative Net Change TNDMPositive Net Change
medical medical-devices
ISRG Rides on da Vinci 5 Momentum: Can This Growth Sustain?
by Indrajit Bandyopadhyay
Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.
JNJNegative Net Change ISRGPositive Net Change STXSNegative Net Change
medical medical-devices
EastGroup Properties (EGP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EGPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
BAXPositive Net Change MCKNegative Net Change CORPositive Net Change GMEDPositive Net Change
medical medical-devices
Is CVS Health's Pharmacy & Consumer Wellness Poised for a Stronger Q3?
by Moumi Mondal
CVS' Pharmacy & Consumer Wellness arm gains traction from tech upgrades, new Rite Aid assets and its evolving CostVantage model.
AMZNPositive Net Change WMTPositive Net Change CVSNegative Net Change
medical medical-devices
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
by Zacks Equity Research
Hims & Hers and LifeMD are reshaping virtual care, but which one leads in earnings growth and platform scale? Let's dive in.
HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
Do Options Traders Know Something About ResMed Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
RMDPositive Net Change
medical medical-devices
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
by Zacks Equity Research
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
BSXNegative Net Change HQYNegative Net Change RVTYNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
Best Momentum Stock to Buy for Oct. 27th
by Zacks Equity Research
PRM, GM and ISRG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27, 2025.
ISRGPositive Net Change GMPositive Net Change PRMPositive Net Change
auto-tires-trucks medical-devices
Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.
BSXNegative Net Change ZBHPositive Net Change GEHCPositive Net Change SOLVPositive Net Change
medical medical-devices
CVS vs. FMS: Which Healthcare Services Stock Has More Upside?
by Moumi Mondal
CVS outpaces FMS in share gains and valuation appeal, with stronger earnings momentum and expanding health services driving its edge.
CVSNegative Net Change FMSNegative Net Change
medical medical-devices
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
PODDNegative Net Change PAHCNegative Net Change VCYTNegative Net Change ITGRNegative Net Change
earnings medical medical-devices